TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques

Yaming Wang,1,5*, Tyler K. Ulland,3* Jason D. Ulrich,2,3,4* Wilbur Song,1 John A. Tzaferis,5 Justin T. Hole,5 Peng Yuan,1 Thomas E. Mahan,2,3,4 Yang Shi,2,3,4 Susan Gilfillan,1 Marina Cell,1 Jaime Grutzendler,9 Ronald B. DeMattos,5 John R. Cirrito,2,3,4 David M. Holtzman,2,3,4 and Marco Colonna1

1Department of Pathology and Immunology, 2Department of Neurology, 3Knight Alzheimer’s Disease Research Center, and 4Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110
3Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285
4Department of Neurology, Yale University, New Haven, CT 06520

Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial receptor that recognizes changes in the lipid microenvironment, which may occur during amyloid β (Aβ) accumulation and neuronal degeneration in Alzheimer’s disease (AD). Rare TREM2 variants that affect TREM2 function lead to an increased risk of developing AD. In murine models of AD, TREM2 deficiency prevents microglial clustering around Aβ deposits. However, the origin of myeloid cells surrounding amyloid and the impact of TREM2 on Aβ accumulation are a matter of debate. Using parabiosis, we found that amyloid–associated myeloid cells derive from brain–resident microglia rather than from recruitment of peripheral blood monocytes. To determine the impact of TREM2 deficiency on Aβ accumulation, we examined Aβ plaques in the 5XFAD model of AD at the onset of Aβ–related pathology. At this early time point, Aβ accumulation was similar in TREM2–deficient and –sufficient 5XFAD mice. However, in the absence of TREM2, Aβ plaques were not fully enclosed by microglia; they were more diffuse, less dense, and were associated with significantly greater neuritic damage. Thus, TREM2 protects from AD by enabling microglia to surround and alter Aβ plaque structure, thereby limiting neuritic damage.

Alzheimer’s disease (AD) is the most common form of late-onset dementia. Key pathological features of AD consist of the deposition of amyloid-β peptide (Aβ) and hyperphosphorylated tau aggregates that, together, are linked with synaptic loss and neuronal cell death, as well as activation of microglia and astrocytes (Holtzman et al., 2011). Rare forms of autosomal dominant inherited AD are caused by mutations in genes involved in the Aβ processing pathway, such as amyloid precursor protein (APP) and presenilin 1 (PSEN1; Tanzi, 2012). The origin of nonfamilial AD is less well understood and may depend on a combination of genetic and nongenetic risk factors (Tanzi, 2012). Recent genome-wide association studies have identified rare variants of genes that encode immune receptors as risk factors (Guerreiro and Hardy, 2014; Karch and Goate, 2015). Among these, the arginine 47 histidine (R47H) variant of triggering receptor expressed on myeloid cells 2 (TREM2) has been found in several cohorts of patients. TREM2 is a cell surface receptor of the Ig superfamily that is expressed in microglia of the central nervous system and in other tissue macrophages, and binds phospholipids and other polyanionic ligands (Paloneva et al., 2002; Daws et al., 2003; Cannon et al., 2012; Wang et al., 2015). TREM2 transmits intracellular signals through the associated adaptor DNA activation protein of 12 kD (DAP12), which recruits the protein tyrosine kinase spleen tyrosine kinase. TREM2 signaling promotes survival, proliferation, phagocytosis, and secretion of cytokines and chemokines (Takahashi et al., 2005; Otero et al., 2009; Wang et al., 2015). TREM2-induced signals also augment activation of integrins, thereby facilitating adhesion and remodeling of the actin cytoskeleton (Takahashi et al., 2005).

We and others have recently examined the impact of TREM2 deficiency on the microglial response to Aβ deposition in mouse models of AD, including APPPS1–21 and 5XFAD mice (Ulrich et al., 2014; Jay et al., 2015; Wang et al., 2015). All studies showed that TREM2 deficiency affects clustering of microglia around the plaques. However, whether Aβ–reactive microgliosis involves resident microglia (Wang et al., 2015) or myeloid cells derived from peripheral blood monocytes (Jay et al., 2015) is still up for debate. Additionally, the analysis of Aβ accumulation in different mouse models of AD yielded inconsistent results.
Aβ -reactive myeloid cells are derived from resident microglia or from infiltrating monocytes in parabiosis experiments. Using this approach, we observed no infiltration of monocytes around Aβ plaques in either 5XFAD or APPPS1-21 mice. Moreover, staining of brain sections for the proliferation marker Ki67 revealed that TREM2 is necessary for local proliferation of microglia around the plaques. To explain the conflicting results regarding the impact of TREM2 deficiency on Aβ accumulation, we hypothesized that whereas TREM2 deficiency results in early impairment of the microglial response to Aβ deposits in all AD models, changes in Aβ burden develop more slowly; therefore, the discrepancies in Aβ accumulation may be a result of the varied timing of the analyses—8 mo in 5XFAD mice (Wang et al., 2015) and 3–4 mo in APPPS1-21 mice (Ulrich et al., 2014; Jay et al., 2015). To test this, we examined microgliosis and Aβ deposition at early time points (4 mo) in Trem2−/− deficient and -sufficient 5XFAD mice. We found that Aβ deposition was quantitatively similar in the presence and absence of TREM2. However, TREM2 did affect microglial clustering and the structure of Aβ plaques at this early time point; in 5XFAD mice lacking TREM2, Aβ plaques appeared more diffuse, had altered Aβ sub-species composition, and were associated with increased neuritic dystrophy compared with those in TREM2-sufficient 5XFAD mice. Collectively, our data demonstrate that TREM2 is required for the early expansion of microglia around Aβ plaques that limits plaque diffusion as well as amyloid-related neuronal damage.

RESULTS AND DISCUSSION
Aβ -reactive myeloid cells derive from brain-resident microglia
It has been proposed that the TREM2-dependent microglial response to Aβ plaques in APPPS1-21 mice relies on the recruitment of blood monocytes (Jay et al., 2015). We first determined whether blood monocytes in 5XFAD mice express TREM2 and hence might respond to putative TREM2 ligands present in peripheral blood during Aβ accumulation. Staining of monocytes from 5XFAD and wild-type mice with anti-TREM2 revealed no detectable expression of TREM2 (Fig. 1 A). However, it remained possible that monocytes up-regulate TREM2 upon infiltrating the brain and, therefore, TREM2 would be required for clustering of infiltrating monocyte around Aβ plaques. To definitively test for contribution of blood monocytes to the microglial pool in 5XFAD mice, we performed parabiosis experiments in which the blood circulation of CD45.2+ 5XFAD mice was joined with that of age-matched congenic CD45.1+ B6 mice (Fig. 1, B–E). Parabiosis was performed in 4-mo-old mice or in 8-mo-old mice. After 4 weeks, tissues were analyzed. Total blood leukocytes and lung alveolar macrophages showed a marked degree of exchange (Fig. 1, B and C). In contrast, nearly all microglia in 5XFAD and B6 mice maintained expression of the original CD45.2 or CD45.1 marker, respectively, consistent with minimal monocyte infiltration (Fig. 1, B–E). Upon expanding this analysis to APPPS1-21 mice we found results consistent with a lack of infiltration of CD45.1+ cells into the brain of CD45.2+ APPPS1-21 mice (Fig. 1, F and G). Thus, the contribution of peripheral monocytes to the microglial pool in both 5XFAD and APPPS1-21 models of AD is negligible.

TREM2 deficiency affects plaque-associated microglial proliferation
We previously observed an impaired microglial response to Aβ in 8-mo-old Trem2−/− 5XFAD mice (Wang et al., 2015). Defective microglial clustering around plaques was also detected at earlier time points in 3- or 4-mo-old Trem2−/− APPPS1-21 mice (Ulrich et al., 2014; Jay et al., 2015). To test whether Trem2−/− 5XFAD mice also had an early microglial defect, we compared the total number of microglia in 4- and 8-mo-old 5XFAD and Trem2−/− 5XFAD mice. Microglial numbers were similar in 4-mo-old 5XFAD and Trem2−/− 5XFAD mice. In contrast, at 8 mo of age, 5XFAD mice had a clear increase in total microglia, whereas age-matched Trem2−/− 5XFAD had fewer microglia (Fig. 2 A). We next assessed the number of plaque-associated microglia in 4-mo-old 5XFAD, Trem2−/− 5XFAD, and Trem2−/− 5XFAD mice. 5XFAD mice had significantly more microglial clustering around plaques than did Trem2−/− and Trem2−/− 5XFAD mice (Fig. 2, B and C). Thus, an impairment of microglial response to Aβ deposits was detectable even at 4 mo of age in Trem2−/− 5XFAD mice.

Given that brain-resident microglia are capable of self-renewal and expansion (Gomez Perdiguer et al., 2013; Greter and Merad, 2013; Prinz and Priller, 2014), we next sought to determine if microglia associated with plaques resulted from the proliferation of resident microglia. We analyzed nuclear localization of Ki-67, a well-characterized proliferation marker, in microglia from 4-mo-old 5XFAD and Trem2−/− 5XFAD mice in relation to their proximity to a plaque (Fig. 2, D–G). In 5XFAD mice, the majority of Ki-67+ microglia detected were in close proximity to Aβ plaques (mean distance = 21.1 μm; Fig. 2, D and E). In contrast, plaque-associated Ki-67+ microglia were nearly undetectable in Trem2−/− 5XFAD mice (Fig. 2 F). Additionally, we observed that Ki-67+ microglia in 5XFAD mice were preferentially located near plaques with a greater volume (Fig. 2 G). As more proliferating microglia were
observed near larger plaques in 5XFAD mice, we sought to determine if there was a correlation between the size of a plaque and the number of microglia associated with it. We found that, in 5XFAD mice, the number of microglia associated with a given plaque was positively correlated to the size of the plaque (Fig. 2H). This correlation was not as strong in Trem2−/− 5XFAD and not apparent in Trem2+/− 5XFAD (Fig. 2H).

Finally, as microglia are phagocytic and have been demonstrated to engulf pieces of plaques, we wished to examine the number of microglia which had internalized portions of plaques in 5XFAD and Trem2−/− 5XFAD
by measuring uptake of methoxy-X04, which binds to fibrillar Aβ (Heneka et al., 2013). Microglia in Trem2⁻/⁻ 5XFAD mice incorporated less methoxy-X04 than microglia from 5XFAD mice (Fig. 2, I and J), corroborating that TREM2 deficiency impairs productive interactions between microglia and plaques. Collectively, these data indicate that TREM2-dependent accrual of resident microglia is a process that initiates early in Aβ deposition and depends at least in part on local proliferation of microglia around growing Aβ plaques.
TREM2 deficiency alters the physical appearance and composition of Aβ plaques

To determine if TREM2 impacted Aβ deposition at 4 mo of age, we compared the total insoluble Aβ1-42 and Aβ1-40 from 5XFAD, Trem2−/− 5XFAD, and Trem2+/− 5XFAD mice in the hippocampus and cortex by ELISA. We found no differences in the total Aβ1-42 or Aβ1-40 present in any of the genotypes (Fig. 3, A–D). Consistent with these findings, we did not detect a significant difference in X-34 staining in the cortices of Trem2+/− 5XFAD mice (Fig. 3 E). However, TREM2 had a remarkable influence on the structure of Aβ plaques. Fibrillar Aβ plaques from 5XFAD mice at 4 mo of age were compact with well-defined, condensed cores and few surrounding diffuse structures (Fig. 3 F). In contrast, plaques from Trem2−/− 5XFAD mice appeared more loosely packed with smaller cores and many fiber-like structures extending outwards (Fig. 3 F). A quantitative morphology index based on the perimeter versus area of Aβ plaques in multiple brain sections confirmed TREM2-dependent differences in the morphology of Aβ plaques (Fig. 3 G). Furthermore, computation of pixels within Aβ plaque images demonstrated that plaque density was also TREM2 dependent (Fig. 3, H and I). Shape and density differences were also apparent in 8-mo-old mice (Fig. 3, F–I).

We sought to determine whether plaques from 5XFAD and Trem2−/− 5XFAD mice also differed in the biochemical profile of the Aβ deposits. It has been previously observed that Aβ plaques contain several Aβ sub species resulting from truncation and/or posttranslational modification of the Aβ1-42 peptides (DeMattos et al., 2012; Kummer and Heneka, 2014), including Aβ1-34, a truncated form of Aβ with a pyroglutamate modification at position 3 (Harigaya et al., 2000). To determine if the accumulation of Aβ sub species was affected by TREM2 deficiency, we analyzed the insoluble fractions of Aβ from the brains of 8-mo-old 5XFAD, Trem2−/− 5XFAD, and Trem2+/− 5XFAD mice by denaturing acid/urea PAGE, followed by immunoblotting using antibodies against various epitopes of Aβ (DeMattos et al., 2002). We observed that the abundance of Aβ1-34 relative to Aβ1-42 was reduced in the hippocampi of Trem2−/− 5XFAD and Trem2+/− 5XFAD mice. In addition, the relative abundance of other Aβ sub species, such as Aβ1-42-1 and Aβ1-42-2, was reduced in a similar fashion in Trem2−/− 5XFAD and Trem2+/− 5XFAD mice (Fig. 3, J and K). Thus, TREM2 deficiency not only influences the physical appearance of the plaques, but also alters the Aβ sub species composition.

TREM2 expression is important in limiting neuronal toxicity during the early stages of Aβ deposition

Because large, swollen, dystrophic axons and dendrites (neurites) are associated with Aβ plaques in AD and in mouse models with Aβ deposition (Masliah et al., 1996; Brendza et al., 2003), we examined whether altered plaque morphology and composition was also associated with increased neuronal damage. We stained sections for the N terminus (NT) of APP (NT-APP), which accumulates in dystrophic neurites, and measured NT-APP+ neuronal processes within 30 µm of Aβ plaques. We found that the number of dystrophic neurites was significantly increased in Trem2−/− 5XFAD mice compared with 5XFAD mice (Fig. 4, A–C). We also stained sections for hyperphosphorylated tau and found an increase in the number and volume of hyperphosphorylated tau punctae in Trem2−/− 5XFAD mice compared with 5XFAD mice (Fig. 4, D–E). Thus, the altered Aβ plaque shape and density associated with TREM2 deficiency observed in Fig. 3 were associated with increased toxicity to neural processes. Overall, these data indicate that TREM2-mediated microglial response is crucial in compacting Aβ plaques and preventing damage to the adjacent axons and dendrites.

Concluding remarks

A previous study proposed that TREM2 is important for filtration of blood-derived monocytes into the brain, which then mediate Aβ plaque-associated reactive microgliosis (Jay et al., 2015). This study was based on phenotypic characterization of microgliosis with monocytic- and microglia-specific markers, along with bone marrow grafts, which enable tracking of congenically marked peripheral monocytes that traffic into the brain. However, phenotypic markers of microglia, such as low expression of CD45 and high expression of the P2Y(12) receptor, are altered upon microglial activation and therefore do not precisely discriminate microglia from monocytes (Butovsky et al., 2014). Moreover, whole-body irradiation before bone marrow grafts causes a blood–brain barrier (BBB) leakage, facilitating an influx of blood monocytes that may obscure the relative contribution of distinct myeloid cell types during Aβ accumulation (Mildner et al., 2011). As parabiosis models do not rely on methods that may compromise the BBB, they may be more reliable than bone marrow grafts for determining the origin of microglia. Our parabiosis experiments indicate that the contribution of peripheral blood monocytes to microgliosis in mouse models of Aβ accumulation with an unperturbed BBB is undetectable. Moreover, staining of brain section with Ki67 suggested that Aβ- associated microgliosis depends at least in part on the proliferation of brain-resident microglia. Consistent with the predominant impact of brain-resident microglia in the response to amyloid, two recent studies showed that in a transgenic mouse model of Aβ deposition in which microglia are depleted after intracranial injection of gangliocyclovir and replaced with infiltrating monocytes, the infiltrating cells co-localize with Aβ plaques only after a long period of time and are not efficient at clearing plaques (Prokop et al., 2015; Varvel et al., 2015).

Recently, microglia around Aβ plaques were shown to form a physical barrier that prevents outward plaque expansion and leads to compact plaque microregions with low Aβ1-42 affinity (Condello et al., 2015). Areas not covered by
microglia are less compact and contain protofibrillar hotspots with high Aβ1-42 affinity, which are associated with more severe axonal dystrophy. Our data show that in the absence of TREM2-mediated microgliosis, Aβ plaques are less dense, more diffuse, and have some alterations in their biochemical features, exemplified by the reduced abundance of various Aβ subspecies in 5XFAD mice. Whether microglia influence the conversion of Aβ1-42 into other Aβ species by enabling Aβ-modifying enzymes to act more efficiently on aggregated forms of Aβ remains an open question. More importantly,

Figure 3. TREM2 deficiency alters physical appearance and biochemical composition of amyloid plaques. (A–D) Accumulation of insoluble Aβ1-42 (A and B) and Aβ1-40 (C and D) in the cortices and hippocampi of 4-mo-old 5XFAD, Trem2+/−, and Trem2−/− mice was determined by ELISA. (E) Deposition of fibrillar Aβ in the cortices determined by X-34 staining. Levels of X-34 signal in the hippocampi were below the threshold of detection. (F–I) Morphology of fibrillar plaques in 4-mo-old 5XFAD and Trem2−/− mice. X-34-reactive fibrillar plaques were visualized using high-resolution confocal microscopy (F) and converted to heat-map images based on pixel intensity (H). Physical appearance of X-34-reactive fibrillar plaques was further quantified based on morphology (G) and pixel intensity (I). Diffuse shape and reduced density were also apparent in 8-mo-old Trem2−/− mice (F and H). (J) Representative urea immunoblots showing the detection of Aβ1-42, Aβ1-42+1, Aβ1-42-1, Aβ1-42-2, and Aβ3-42 from insoluble fractions of hippocampi from 5XFAD mice. (K) Quantification of insoluble Aβ species by urea immunoblots in the cortices and hippocampi of 5XFAD, Trem2+/−, and Trem2−/− mice. Abundance of Aβ1-42+1, Aβ1-42-1, Aβ1-42-2, and Aβ3-42 relative to Aβ1-42 is shown. Amount of Aβ used for standard curves are indicated. Bar, 10 µm. *, P < 0.05; ** P < 0.01; ****, P < 0.0001, Mann-Whitney (G and I), two-way ANOVA (E and K). Data represent a total of 8–14 mice per group in A–E, eight mice per group in F–I and five mice per group in K. For confocal images, a total of four random HPF were analyzed per mouse. Error bar represents mean ± SEM.
The altered Aβ plaque morphology associated with TREM2 deficiency led to enhanced toxicity potential, as indicated by the increase in neuritic dystrophy. These results indicate that TREM2 has a major impact on the early containment of plaque diffusion by microglia. This impact is appreciable even at 4 mo of age, although the total Aβ present in TREM2-deficient mice is similar. We postulate that lack of this function for a long period of time leads to the increase in hippocampal Aβ1-42 levels in 8-mo-old TREM2-deficient mice that we previously reported (Wang et al., 2015). Collectively, our studies highlight the protective role of TREM2 expression in brain-resident microglia by influencing the structure, biochemical composition, and toxicity of Aβ deposits and provide novel insights into the mechanisms by which TREM2 acts in the early stages of AD development.

Figure 4. Neuritic dystrophy and the amounts of phospho-tau in proximity to plaques are markedly increased in the absence of TREM2. (A–C) Neuritic dystrophy in 5XFAD and Trem2−/− 5XFAD mice was visualized using 22C11 mAb against the APP N terminus (APP-NT). (A) Representative images show APP-NT+ neurites (green), Aβ plaques (X-34; red), and nuclei (To-pro3; blue). (B and C) Quantification of total volume and numbers of APP-NT+ neurites within 30 µm of Aβ plaques. (D–F) Hyperphosphorylated tau in 5XFAD and Trem2−/− 5XFAD mice. Sections were stained with anti–phospho-tau antibody (AT8; green) and Aβ plaques (red; D). Total volume of AT8+ neurites (E) and the number of AT8+ spots per HPF (F) were quantified. Bar, 20 µm. *, P < 0.05; ****, P < 0.0001, by Mann-Whitney. Data represent a total of four to eight mice per group. For confocal images, a total of four random HPF were analyzed per mouse. Error bar represents mean ± SEM.

MATERIALS AND METHODS

Mice. Trem2+/− mice were previously described (Turnbull et al., 2006). 5XFAD mice (Oakley et al., 2006) were purchased from The Jackson Laboratory (MMRRC) and crossed to Trem2+/− mice to generate Trem2+/−/5XFAD and Trem2−/−5XFAD mice (Wang et al., 2015). Parabiotic mice were joined by the surgery core in the Hope Center for Neurological Disorders (Washington University, St. Louis, MO). In brief, the skin along the opposite flanks of parabiotic pairs was joined under general anesthesia and pairs were housed for the indicated postoperative time. All animal studies were approved by the Washington University Animal Studies Committee.

Preparation of brain samples. For histological analysis, mice were anesthetized with ketamine and perfused with ice-cold PBS. Right–brain hemispheres were fixed in 4% PFA overnight and placed in 30% sucrose before freezing and cutting on a freezing sliding microtome. Serial 40-µm coronal sections of the brain were collected from the rostral anterior commissure to caudal hippocampus as landmarks. For biochemical analysis, cortices, and hippocampi of the left–brain hemispheres were dissected out and flash frozen in liquid nitrogen.

Confocal imaging and quantification. 40-µm floating sections were stained with Iba-1 (Wako Pure Chemical Industries), X-34, and To-pro-3 for visualization of microglia, plaques, and nuclei, respectively. Confocal images were collected using a Nikon A1R+ confocal microscope. 4–5 z-stack images (447 × 447 × 30 µm; 1.25 µm thickness) were acquired per animal in random cortical regions and hippocampal regions. Images were then processed with Imaris (Bitplane). Coordinates of microglia and the location and volume of Aβ plaques were identified using the Particle and Surface function, respectively, and imported into Matlab (Mathworks). Number of microglia within a 15- and 30-µm radius were then determined using automated script. Dystrophic neurites were identified using 22C11 antibody against the N terminus of APP (EMD Millipore) followed by Alexa Fluor 555–conjugated anti–mouse IgG. Proliferating cells were identified using an anti–Ki-67-biotin (SolA15; eBioscience), followed by Alexa Fluor 488–conjugated streptavidin (Molecular Probes). Hyperphosphorylated tau was detected with AT8 antibody (Thermo Fisher Scientific). For plaque morphology analysis, high-resolution images were collected at 60× magnification with 1.5× digital zoom. Maximum intensity projection of the z-stack for each plaque was subsequently used for morphological analysis. To trace the shape of plaques, we applied a combination of intensity thresholds and edge detection in Matlab. First, the mean intensity of the brightest 10 pixels in the image (max intensity) was used to normalize the range. Pixels with intensity >0.5 times this max intensity formed a bright mask, and pixels <0.1 times this max formed a background mask. Next, edges were detected using the Laplacian of Gaussian method and dilated to generate a closed object. This object was overlaid with the bright mask, with the back-
ground mask used to eliminate edges that may appear in the background pixels. Finally, holes <50 pixels in the resulting plaque tracing were filled in, and the entire shape was smoothed out by image erosion with a diamond-shaped element to obtain the final shape. In summary, pixels brighter than 0.5 times max were included, pixels dimmer than 0.1 times max were excluded, and pixels between those values were determined by edge detection. The density index was defined as (no. perimeter pixels) \( \times 4\pi / \text{total no. of pixels}; \) this increases with shape complexity, but is roughly size invariant. A perfect circle of any size would have a value near 1, and more complex shapes would have larger values.

The diffuseness of staining was also assessed using the z-projected plaque image. First, pixels <1% of max intensity were discarded as background pixels that were not part of the plaque. For this analysis, the shape tracing described above, which favors crisp edges, was not included so that more diffusely stained parts of the image could still be included in quantification. The cumulative intensity curve for the plaque image, starting with the brightest pixels and adding on progressively dimmer pixels, was compared with that of a “perfectly dense” curve, where all signal intensity is accounted for by maximum-intensity pixels. The area between these curves, normalized to the total intensity and the number of pixels, represents the deviation from a uniformly dense plaque. To obtain an index of density ranging from 0 to infinity, this area was inverted, and the lower limit of the resulting index, 2, was subtracted.

**Denaturing acid/urea polyacrylamide gel electrophoresis (PAGE) and ELISA.** A mouse anti-\(\beta\)p3-42 antibody (21F12) was used for capture and biotinylated mouse anti-\(\beta\)p3-42 antibody (mE8) was used for detection of \(\beta\)p3-42 or \(\beta\)p3-42, respectively (DeMattos et al., 2012), followed by streptavidin HRP (SouthernBiotech). All ELISAs were developed using Super Slow ELISA TMB (Sigma-Aldrich) and absorbance read on a Bio-Tek Epoch plate reader at 650 nm. The standard curves for each assay used synthetic human \(\beta\)p3-42 or \(\beta\)p3-42 peptide (AnaSpec). Denaturing Acid/Urea PAGE was performed as previously described (DeMattos et al., 2002). Subsequent standard immunoblotting was used for \(\beta\)A identification.

**In vivo phagocytosis assay for fibrillar \(\beta\)A.** Mice were injected with methoxy-X04 (R&D Systems) at 10 mg/kg in a PBS/DMSO mixture at 1:1 ratio. Brains were isolated 3 h after injection and made into single-cell suspension as previously described (Heneka et al., 2013). Frequencies of methoxy-X04+ microglia cells were determined by flow cytometry using a Canto II (BD) and analyzed using FlowJo (Tree Star).

**Statistics.** Data in figures are presented as mean ± SEM. All statistical analysis was performed using Prism (GraphPad Software). Statistical analysis to compare the mean values for multiple groups was performed using a one- or two-way ANOVA with correction for multiple comparisons. Comparison of two groups was performed using a two-tailed unpaired t test (Mann Whitney). Values were accepted as significant if \(P \leq 0.05\).
3 is a major component of the amyloid deposits in the Alzheimer's disease brain. *Biochem. Biophys. Res. Commun.* 276:422–427. http://dx.doi.org/10.1006/bbrc.2000.3490

Heneka, M.T., M.P. Kummer, A. Stutz, A. Delekate, S. Schwartz, A. Vieira-Saëcker, A. Grieb, D. Ast, A. Remus, T.C. Tzeng, et al. 2013. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. *Nature.* 493:674–678. http://dx.doi.org/10.1038/nature11729

Holtzman, D.M., J.C. Morris, and A.M. Goate. 2011. Alzheimer's disease: the challenge of the second century. *Sci. Transl. Med.* 3:77sr1. http://dx.doi.org/10.1126/scitranslmed.3002369

Jay, T.R., C.M. Miller, P.J. Cheng, L.C. Graham, S. Bemiller, M.L. Brohier, G. Xu, D. Margevicius, J.C. Karlo, G.L. Souza, et al. 2015. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. *J. Exp. Med.* 212:287–295. http://dx.doi.org/10.1084/jem.20142322

Karch, C.M., and A.M. Goate. 2015. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biol. Psychiatry.* 77:43–51. http://dx.doi.org/10.1016/j.biopsych.2014.05.006

Kummer, M.P., and M.T. Heneka. 2014. Truncated and modified amyloid-beta species. *Alzheimers Res. Ther.* 6:28. http://dx.doi.org/10.1186/alzrt258

Masliah, E., A. Susk, M. Mallory, L. Mucke, D. Schenk, and D. Games. 1996. Comparison of neurodegenerative pathology in transgenic mice overexpressing V177F beta-amyloid precursor protein and Alzheimer's disease. *J. Neurosci.* 16:5795–5811

Mildner, A., B. Schlevoigt, K. Kierdorf, C. Böttcher, D. Erny, M.P. Kummer, M. Quinn, W. Brück, I. Bechmann, M.T. Heneka, et al. 2011. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. *J. Neurovirol.* 31:11159–11171. http://dx.doi.org/10.1523/JNEUROSCI.6209-10.2011

Oakley, H., S.L. Cole, S. Logan, E. Maus, P. Shao, J. Craft, A. Gullozet-Bongaarts, M. Ohno, J. Dusterhoff, L. Van Eldik, et al. 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. *J. Neurovirol.* 26:10129–10140. http://dx.doi.org/10.1523/JNEUROSCI.1202-06.2006

Otero, K., L.R. Turnbull, P.L. Peliani, W. Vermi, E. Cerutti, T. Aoshi, I. Tassi, T. Takai, S.L. Stanley, M. Miller, et al. 2009. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAPI2 and beta-catenin. *Nat. Immunol.* 10:734–743. http://dx.doi.org/10.1038/ni.1744

Paloneva, J., T. Manninen, G. Christman, K. Hovanes, J. Mandelin, R. Adolfsson, M. Bianchin, T. Bird, R. Miranda, A. Salmaggi, et al. 2002. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. *Am. J. Hum. Genet.* 71:656–662. http://dx.doi.org/10.1086/342259

Prinz, M., and J. Priller. 2014. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. *Nat. Rev. Neurosci.* 15:300–312. http://dx.doi.org/10.1038/nrn3722

Prokop, S., K.R. Miller, N. Drost, S. Handrick, V. Mathur, J. Luo, A. Wégner, T. Wynn-Coray, and E.L. Heppner. 2015. Impact of peripheral myeloid cells on amyloid-β pathology in Alzheimer's disease-like mice. *J. Exp. Med.* 212:1811–1818. http://dx.doi.org/10.1084/jem.20150479

Takahashi, K., C.D. Rochford, and H. Neumann. 2005. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. *J. Exp. Med.* 201:647–657. http://dx.doi.org/10.1084/jem.20041611

Tanzi, R.E. 2012. The genetics of Alzheimer disease. *Cold Spring Harb. Perspect. Med.* 2:10. http://dx.doi.org/10.1101/cshperspect.a006296

Tanzi, R.E. 2015. TREM2 and Risk of Alzheimer's Disease—Friend or Foe? *N. Engl. J. Med.* 372:2564–2565. http://dx.doi.org/10.1056/NEJMcibr1503954

Turnbull, I.R., S. Gilfillan, M. Cell a, T. Aoshi, M. Miller, L. Piccio, M. Hernandez, and M. Colonna. 2006. Cutting edge: TREM-2 attenuates macrophage activation. *J. Immunol.* 177:3520–3524. http://dx.doi.org/10.4049/jimmunol.177.6.3520

Ulrich, J.D., M.B. Finn, Y. Wang, A. Shen, T.E. Mahan, H. Jiang, E.R. Stewart, L. Piccio, M. Colonna, and D.M. Holtzman. 2014. Altered microglial response to Aβ in APP/PS1-21 mice heterozygous for TREM2. *Mol. Neurodegener.* 9:20. http://dx.doi.org/10.1186/1750-1326-9-20

Varwel, N.H., S.A. Grathwohl, K. Degenhardt, C. Bosch, M. Jucker, and J.J. Neher. 2015. Replacement of brain-resident myeloid cells does not alter cerebral amyloid-β deposition in mouse models of Alzheimer's disease. *J. Exp. Med.* 212:1803–1809. http://dx.doi.org/10.1084/jem.20150478

Wang, Y., M. Cella, K. Mallinson, J.D. Ulrich, K.L. Young, M.L. Robinette, S. Gilfillan, G.M. Krishnan, S. Sudhakar, B.H. Zinselmeyer, et al. 2015. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. *Cell.* 160:1061–1071. http://dx.doi.org/10.1016/j.cell.2015.01.049